AgomAb Therapeutics NV
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AgomAb Therapeutics NV
But the cash will probably not be enough to prove its lead compound’s efficacy for a severe form of Crohn’s disease.
Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.
Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.
The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
- Large Molecule
- Other Names / Subsidiaries
- Origo Biopharma S.L.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.